Add like
Add dislike
Add to saved papers

Citalopram-Induced Long QT Syndrome and the Mammalian Dive Reflex.

While SCUBA diving, a 44-year-old Caucasian patient had an abnormal cardiac rhythm, presumably Torsade de Pointes (TdP), during the initial descent to depth. Upon surfacing, she developed ventricular fibrillation and died. The patient had been treated for mild depression for nearly a year with citalopram 60 mg per day, a drug known to cause prolonged QT interval. She had also been treated with two potentially hepatotoxic drugs. Liver impairment causes selective loss of cytochrome P450 (CYP) 2C19 activity, the major pathway for metabolism of citalopram. The post mortem blood level of citalopram was 1300 ng/mL. The patient was found to be an intermediate metabolizer via CYP2D6, the major pathway for metabolism of desmethylcitalopram; the level of which was also abnormally high. It is suggested that drug-induced long QT syndrome (DILQTS), caused by citalopram, combined with the mammalian dive reflex triggered malignant ventricular rhythms resulting in the patient's death. It is further suggested that, in general, the dive reflex increases the risk of fatal cardiac rhythms when the QT interval is prolonged by drugs.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app